GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Eravacycline (Xerava)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Xerava

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

XERAVA - adult cIAI dosing and renal statement

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
No renal-function dose bands specified for this summary.

Dosing / renal protocol and limits

Adults with complicated intra-abdominal infection: 1 mg/kg IV every 12 hours, infused over approximately 60 minutes, for 4-14 days according to response. This is not a cUTI indication.

Renal impairment does not require dose adjustment. Hemodialysis is not expected to remove substantial drug.

Severe hepatic impairment is different: Child-Pugh C uses 1 mg/kg every 12 hours on day 1, then every 24 hours. Strong CYP3A inducers require 1.5 mg/kg every 12 hours. Confirm interacting drugs and hepatic function rather than applying the renal statement to these situations.

Source revision: DailyMed updated 2025-03-31; prescribing information revised 2025-03 | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4b188d4-f467-470c-ad7b-25ffbdd8862a

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

XERAVA - adult cIAI dosing and renal statement

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Xerava

Adult product-specific renal information; not a complete prescribing regimen.

Renal method: Renal impairment/ESRD; no numerical renal dose bands.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

UCSF - eravacycline

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeXERAVA - adult cIAI dosing and renal statementGlobalRPh RX List - XeravaUCSF - eravacycline
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4b188d4-f467-470c-ad7b-25ffbdd8862a

Product and population scope

Adult Eravacycline (Xerava). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-eravacycline · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

XERAVA - adult cIAI dosing and renal statement

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2025-03-31; prescribing information revised 2025-03
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adults with complicated intra-abdominal infection: 1 mg/kg IV every 12 hours, infused over approximately 60 minutes, for 4-14 days according to response. This is not a cUTI indication.

Renal impairment does not require dose adjustment. Hemodialysis is not expected to remove substantial drug.

Severe hepatic impairment is different: Child-Pugh C uses 1 mg/kg every 12 hours on day 1, then every 24 hours. Strong CYP3A inducers require 1.5 mg/kg every 12 hours. Confirm interacting drugs and hepatic function rather than applying the renal statement to these situations.

RDM30-091-eravacycline-1 · Source locator: XERAVA - adult cIAI dosing and renal statement; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4b188d4-f467-470c-ad7b-25ffbdd8862a
Retrieved
2026-09-05
DailyMed Set ID
a4b188d4-f467-470c-ad7b-25ffbdd8862a
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2025-03-31; prescribing information revised 2025-03
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
1306211a715a1b82ff2a60314dea07fcae25d96eb4ffccc258f25390b986de3f
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Xerava

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult product-specific renal information; not a complete prescribing regimen.

Renal method: Renal impairment/ESRD; no numerical renal dose bands.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal dose adjustment is necessary. The source includes an ESRD pharmacokinetic study without a clinically important change in exposure. The renal statement does not remove separate hepatic dose or drug-interaction requirements, and it does not supply a CRRT-specific dosing algorithm.

RDM34-rxlist-xerava-drug-C1 · Source locator: Use in specific populations: renal impairment; clinical pharmacology: ESRD.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xerava-drug/
Retrieved
2026-09-07
Renal-function method
Renal impairment/ESRD; no numerical renal dose bands.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only, not original HTML, PDF or SPL bytes.
Local summary SHA-256
661cd3809d1ebf44776da89b6e80506223b76c4f6672a20dab75c7c0827d515d
Separate professional-source layer

University and professional protocols

Professional

UCSF - eravacycline

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult dose: 1 mg/kg IV every 12 hours using total body weight. No routine reduction is recommended for renal dysfunction or hemodialysis. With a strong CYP3A4 inducer, the listed regimen is 1.5 mg/kg every 12 hours.

Severe hepatic impairment is a separate adjustment: 1 mg/kg every 12 hours for two doses, then every 24 hours. Do not confuse hepatic or interaction adjustments with kidney-function dosing.

RDM30-050-eravacycline-1 · Source locator: UCSF - eravacycline; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/eravacycline
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
ce7c09c48b793e4a0847de7bd1eadcfc24c8cd113cf38fa1a5910ec8ed5902ba

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4b188d4-f467-470c-ad7b-25ffbdd8862a
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
b5f6e376ffe0d6e79dba6348060ba1379d2cc9b5937f5202773fc234de7d83f1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report